Tacrine is the first acetylcholinesterase inhibitor (AChEI) introduced in therapy for the treatment of Alzheimer's disease (AD) [1], but its clinical application is limited because of the side effects in gastrointestinal tract such as nausea, vomiting, and regurgitation [3]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.